Novartis digs deeper in radiopharma with $1.75bn Mariana buy
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
Mobile app guides patients through surgical recovery
Hospital staff in the UK have developed and piloted an app that can help patients monitor their progress to recovery after surgeries and feed information back to their car
RNA glioblastoma vaccine shows promise in first human trial
A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial.
Wegovy sales double, as starting restrictions start to lift
Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy
Astellas expands Poseida alliance on solid tumour CAR-Ts
Astellas has clearly been impressed with a partnership signed last August with Poseida Therapeutics on the development of cell therapies for solid tumours, as it has just
Partner Content
Final FDA rule on LDTs creates a paradigm shift for laborato...
WASHINGTON, D.C., April 30, 2024 –The Food and Drug Administration’s (FDA) final rule has reclassified laboratory developed tests (LDTs) as medical devices, according to Avalere.
FT US PHARMA AND BIOTECH SUMMIT
2024 is a pivotal year for the US healthcare sector.
4th Next Generation Gene Therapy Vectors Summit 2024
Accelerate your capsid and payload design with the 4th Next Generation Gene Therapy Vectors Summit (June 12-14, Boston), the industry’s only hub for covering the latest advances and innovations in
2nd ADC Toxicity Summit 2024
Improving Prediction & Translation of ADC Toxicities to Drive More Tolerable ADCs Successfully Into & Through Clinical Development
15th World Bispecific Summit 2024
Radically Optimize Bi, Tri & Multispecific Antibodies to Enhance Target Discovery, Mechanistic Diversity & Clinical Translation to Maximize the Therapeutic Index & Enhance Combi